Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Millennium
Nature Publishes Preclinical Data on an Inhibitor of a Novel Target Discovered by Millennium
April 21st, 2009
Takeda Pharmaceutical Company and Millennium: The Takeda Oncology Company announced publication of an article describing the discovery of MLN4924—a small molecule inhibitor of the NEDD8-Activating Enzyme (NAE) in the journal Nature. NAE modulates the level of proteins critical for the regulation of cancer cell growth and survival pathways. Preclinical data show that MLN4924 inhibition of NAE function alters these important cancer pathways and results in cancer cell death. Data published in Nature demonstrate that MLN4924 not only inhibits detectable NAE pathway function in cancer cells in vitro but also does the same in human tumor xenografts in murine models leading to...
Source: Cancer Weekly (2009-04-21)
|
